Science Daily: Pharmacology News
MAY 31, 2023
Scientists have taken the world's first X-ray SIGNAL (or SIGNATURE) of just one atom. This groundbreaking achievement could revolutionize the way scientists detect the materials.
Forbes: Drug Truths
MAY 15, 2023
In the midst of the Covid-19 pandemic, when thousands of people were dying on a daily basis, the hopes of the world rested on the biopharmaceutical industry for rapidly finding vaccines, antibodies and therapeutants.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Hunter
MAY 31, 2023
This article compiles 20+ recent small molecules of general interest in the news in April 2023, with structures where they are available. Capacity Bio’s MAS Receptor Agonists with $35M Raised for FIH Clinical Trials MAS modulator from WO2022165189 example 107 New start-up Capacity Bio backed by RA Capital, Insight Partners, and Remiges Ventures with $35 million funding is working on taking first-in-class mitophagy agonists into clinical trials, which are expected to start in 2024.
Collaborative Drug
MAY 1, 2023
Upcoming Webinar: Artificial Intelligence Drug Discovery — Where are we now?
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Covalent Modifiers
MAY 29, 2023
Fu, L., Jung, Y., Tian, C. et al. Nat Chem Biol (2023). [link] With an eye toward expanding chemistries used for covalent ligand discovery, we elaborated an umpolung strategy that exploits the ‘polarity reversal’ of sulfur when cysteine is oxidized to sulfenic acid, a widespread post-translational modification, for selective bioconjugation with C-nucleophiles.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Science Daily: Pharmacology News
MAY 24, 2023
Taking a daily multivitamin may help slow age-related memory decline, a new study has found.
Drug Patent Watch
MAY 16, 2023
On NPR’s All Things Considered, Sydney Lupkin asked DrugPatentWatch if drug patents could be used to identify injector pens which could then be swapped to fix drug shortages. Referring to… The post NPR and DrugPatentWatch – Can drug injector pens be swapped? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Hunter
MAY 21, 2023
This “journal club” article highlights five recent articles of general interest to drug discovery scientists, including reviews on therapeutic areas of interest, principles and areas of medicinal chemistry and pharmacology, and a synthetic transformation worth keeping in mind. 1. A “Magic Chloro” Med. Chem. Review D. Chiodi and Y. Ishihara (Vividion) J.
Collaborative Drug
MAY 12, 2023
CDD Exhibiting and Presenting at Bio-IT World, Boston, May 16-18, 2023
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Covalent Modifiers
MAY 24, 2023
Burns, A.R., Baker, R.J., Kitner, M. et al. Selective control of parasitic nematodes using bioactivated nematicides. Nature (2023) [link] Parasitic nematodes are a major threat to global food security, particularly as the world amasses 10 billion people amid limited arable land. Most traditional nematicides have been banned owing to poor nematode selectivity, leaving farmers with inadequate means of pest control.
Drug Discovery Today
MAY 26, 2023
BARCELONA/LONDON, 25.05.23: Seqera Labs, the leading provider of secure workflow orchestration software in the life sciences sector, has partnered with Genomics England, the government-owned company that launched the 100,000 Genomes Project in partnership with the NHS. The new collaboration between Seqera Labs and Genomics England will enable whole genome analysis to be carried out at a larger scale with greater efficiency, helping more patients benefit from genomic healthcare and equipping rese
Science Daily: Pharmacology News
MAY 18, 2023
Fifty-three percent of the world's largest freshwater lakes are in decline, storing less water than they did three decades ago, according to a new study. The study analyzed satellite observations dating back decades to measure changes in water levels in nearly 2,000 of the world's biggest lakes and reservoirs. It found that climate change, human consumption and sedimentation are responsible.
Drug Patent Watch
MAY 22, 2023
Introducing DrugChatter.com: Empowering Access to Biopharmaceutical Drug Insights through AI Chat We are pleased to introduce DrugChatter.com, a groundbreaking platform that redefines the way professionals obtain concise, cited information on… The post DrugChatter.com: AI Chat for Biopharmaceutical Drug Insights appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Hunter
MAY 22, 2023
We couldn’t include everything in Molecules of the Month, but here’s a round-up of up of 16 additional molecules of potential interest that we didn’t have space for in April, including a highly selective caspase inhibitor from a non-catalytic cysteine, a GPR40 AgoPAM from BMS with activity on GLP-1, a few examples of both on- and off-target toxicities, and several clinical candidates. 1.
Collaborative Drug
MAY 4, 2023
Drug Discovery Industry Roundup with Barry Bunin — May 3, 2023
Covalent Modifiers
MAY 23, 2023
Elena Xerxa, Filip Miljković, and Jürgen Bajorath Journal of Medicinal Chemistry 2023 DOI: 10.1021/acs.jmedchem.3c00621 Large-scale analysis of public human and mouse protein kinase inhibitor (PKI) data identified more than 155,000 human PKIs (and ∼3000 murine PKIs), for which reliable activity measurements were available. Human PKIs were active against 440 kinases (85% coverage of the kinome).
Drug Discovery Today
MAY 26, 2023
New branding reflects customer-centric approach and showcases pioneering, single cell analysis technology Rebrand follows a period of significant growth for the Company, including key leadership team appointments, state-of-the-art facility expansion, and new scientific partnerships
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Science Daily: Pharmacology News
MAY 31, 2023
Even without nerves, plants can sense when something touches them and when it lets go, a study has found. In a set of experiments, individual plant cells responded to the touch of a very fine glass rod by sending slow waves of calcium signals to other plant cells, and when that pressure was released, they sent much more rapid waves. While scientists have known that plants can respond to touch, this study shows that plant cells send different signals when touch is initiated and ended.
Chemical Biology and Drug Design
MAY 31, 2023
Hydrazide-hydrazone derivatives were synthesized and tested for their ability to inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). In addition, molecular docking and ADME studies were carried out. Abstract A series of hydrazide-hydrazone imine derivative compounds (3a–k) were synthesized and their structures characterized using FTIR, 1 H, and 13 C (NMR) spectroscopic methods.
Drug Hunter
MAY 21, 2023
This article highlights six recent articles of interest in the field of targeted protein degradation including but not limited to potentially new ligases, recruiting motifs, and a discussion on the feasibility of CNS-penetrant degraders. 1. “Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings” Novartis, Basel, CH + Cambridge, MA BioRxiv , April 14, 2023 This Novartis study identified a novel non-covalent ligand for the E3 ligase receptor DCAF1 for use in
ASPET
MAY 15, 2023
Nitrogen mustard (NM) is a cytotoxic vesicant known that causes pulmonary injury that can progress to fibrosis. NM toxicity is associated with an influx of inflammatory macrophages in the lung. Farnesoid X Receptor (FXR) is a nuclear receptor involved in bile acid and lipid homeostasis that has anti-inflammatory activity. In these studies, we analyzed the effects of FXR activation on lung injury, oxidative stress and fibrosis induced by NM.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Covalent Modifiers
MAY 22, 2023
Yi Zhang, Hong Yang, Bingbing Li, Jiayi Li, Huaxuan Li, Qiongyu Shi, Bang Li, Zekun Wang, Jiahong Zheng, Ying Zhang, Hui Dong, Xun Huang, and Yuanxiang Wang Journal of Medicinal Chemistry 2023 DOI: 10.1021/acs.jmedchem.3c00504 The first-generation enhancer of zeste homologue 2 (EZH2) inhibitors suffer from several limitations, such as high dosage, cofactor S-adenosylmethionine (SAM) competition, and acquired drug resistance.
Drug Discovery Today
MAY 25, 2023
The Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London. Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines.Expansion follows recent acceptance of a Drug Master File and first investigational new drug application using doggybone DNA.
Science Daily: Pharmacology News
MAY 25, 2023
There is a massive, mineral-rich region in the Pacific Ocean -- about twice the size of India -- called the Clarion-Clipperton Zone (CCZ), which has already been divided up and assigned to companies for future deep-sea mining. To better understand what may be at risk once companies start mining, a team of biologists has built the first 'CCZ checklist' by compiling all the species records from previous research expeditions to the region.
Chemical Biology and Drug Design
MAY 30, 2023
Eleven 1,6- and 1,3-substituted xanthone compounds were designed and synthesized, of which four were new compounds. Their α -glucosidase inhibitory activities in vitro and in silico were evaluated. This study provided a theoretical basis for the rapid discovery and structural modification of non-competitive xanthone inhibitors of α -glucosidase. Abstract α -glucosidase inhibitors (AGIs) were commonly used in clinical for the treatment of type 2 diabetes.
Drug Hunter
MAY 18, 2023
Dian Su’s journey from chemistry and proteomics to the DMPK of drug conjugates Following a different path comes naturally to Dian Su, Senior Director of DMPK at Bicycle Therapeutics. From a childhood in a small village in China’s northeast Shandong province to her work examining the drug metabolism and pharmacokinetics (DMPK) of antibody-drug conjugates (ADCs) and Bicycle toxin conjugates ® (BTCs), Dian has always looked to forge something new.
Expert insights. Personalized for you.
279 
Let's personalize your content